Company / SG&A Expense
Myriad Genetics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$256.8M
FY2025
5-year range
$256.8M / $572.9M
FY2021-FY2025
Trend
-6.9%
vs FY2024
Sector context
#62 of 213
Health Care
What the data says
At $257M, Myriad Genetics, Inc.'s sg&a expense ranks #152 of 213 in the Health Care sector. SG&A Expense has fluctuated over the past 10 years, ranging from $257M in FY2025 to $573M in FY2023.
Based on SEC 10-K filings.
$257M in FY2025 with a 5-year CAGR of -12.7%.
Improved from $573M to $257M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -20.7%
- 5-Year CAGR
- -12.7%
- 10-Year CAGR
- -
Sector benchmark
#152 of 213 in Health CareTop 71% of 213This company $256.8M Sector average $722.3M
▼
-64.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -12.7%, indicating a declining trend.
- In FY2025, sg&a expense decreased 6.9% year-over-year.
- Ranks #62 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $256.8M | -6.9% |
| FY2024 | $275.9M | -51.8% |
| FY2023 | $572.9M | +11.3% |
| FY2022 | $514.7M | -4.3% |
| FY2021 | $537.8M | +6.0% |
| FY2020 | $507.3M | +15.3% |
| FY2019 | $439.9M | +1.1% |
| FY2018 | $435.0M | -1.1% |
| FY2017 | $439.9M | +22.5% |
| FY2016 | $359.2M | -1.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026